Barrett’s Debate: How to Follow, How to Treat?
BE prevalence–54 sec http://www.ncbi.nlm.nih.gov/pubmed/?term=12145799
who should do it?–2:14
who should have it?–2:49
histologic progression of BE–3:29
Keyword(s): Barrx, BE, cost-utility analysis, EAC, endoscopic ablative therapy, erosive esophagitis, esophageal adenocarcinoma, esophagectomy, flow cytometry, gastroenterologist, HGD, histology, invasive cx, LGD, metaplasia, NBI, neoadjuvant CRT, nonsurgical management, PDT, Photofrin, reflux disease, RFA, UGI endoscopist